Log in

Xeris Pharmaceuticals Stock Forecast, Price & News

-0.05 (-1.09 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $4.53
50-Day Range
MA: $5.13
52-Week Range
Now: $4.53
Volume560,222 shs
Average Volume1.86 million shs
Market Capitalization$221.86 million
P/E RatioN/A
Dividend YieldN/A
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Read More
Xeris Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XERS



Sales & Book Value

Annual Sales$2.72 million
Book Value$0.53 per share


Net Income$-125,580,000.00
Net Margins-2,037.97%


Market Cap$221.86 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
-0.05 (-1.09 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

How has Xeris Pharmaceuticals' stock price been impacted by Coronavirus?

Xeris Pharmaceuticals' stock was trading at $2.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XERS stock has increased by 104.1% and is now trading at $4.53.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Xeris Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xeris Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Xeris Pharmaceuticals?

Wall Street analysts have given Xeris Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Xeris Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Xeris Pharmaceuticals

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) issued its quarterly earnings data on Monday, November, 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.19. Xeris Pharmaceuticals had a negative net margin of 2,037.97% and a negative return on equity of 435.27%.
View Xeris Pharmaceuticals' earnings history

What price target have analysts set for XERS?

4 equities research analysts have issued twelve-month target prices for Xeris Pharmaceuticals' stock. Their forecasts range from $10.00 to $15.00. On average, they expect Xeris Pharmaceuticals' share price to reach $12.75 in the next year. This suggests a possible upside of 181.5% from the stock's current price.
View analysts' price targets for Xeris Pharmaceuticals

Are investors shorting Xeris Pharmaceuticals?

Xeris Pharmaceuticals saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 14,500,000 shares, a decline of 18.0% from the October 15th total of 17,680,000 shares. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is currently 4.6 days.
View Xeris Pharmaceuticals' Short Interest

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the following people:
  • Mr. Paul R. Edick, Chairman & CEO (Age 64, Pay $974.06k)
  • Mr. John P. Shannon, Pres & COO (Age 58, Pay $628.15k)
  • Ms. Beth P. Hecht, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $515.8k)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 56)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
  • Dr. Kenneth E. Johnson Pharm.D., Pharm. D., Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs (Age 57)
  • Mr. Kevin McCulloch, Sr. VP of Global Operations & Bus. Devel.

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), ArrowMark Colorado Holdings LLC (4.24%), Deltec Asset Management LLC (1.84%), State Street Corp (1.46%), Voloridge Investment Management LLC (0.86%) and IHT Wealth Management LLC (0.42%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Paul R Edick, Redmile Group, Llc and Steven Prestrelski.
View institutional ownership trends for Xeris Pharmaceuticals

Which major investors are selling Xeris Pharmaceuticals stock?

XERS stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Morgan Stanley, and ExodusPoint Capital Management LP.
View insider buying and selling activity for Xeris Pharmaceuticals

Which major investors are buying Xeris Pharmaceuticals stock?

XERS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Deltec Asset Management LLC, Voloridge Investment Management LLC, Cornerstone Wealth Management LLC, State Street Corp, IHT Wealth Management LLC, Independent Advisor Alliance, and The Manufacturers Life Insurance Company . Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, John Patrick Shannon Jr, Paul R Edick, and Redmile Group, Llc.
View insider buying and selling activity for Xeris Pharmaceuticals

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $4.53.

How big of a company is Xeris Pharmaceuticals?

Xeris Pharmaceuticals has a market capitalization of $221.86 million and generates $2.72 million in revenue each year. The company earns $-125,580,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Xeris Pharmaceuticals employs 188 workers across the globe.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is www.xerispharma.com.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.